Genedrive (GB:GDR) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genedrive PLC has announced substantial progress in the UK, with initial orders exceeding £100,000 for their Genedrive MT-RNR1 test from five new hospitals in Greater Manchester. This rapid, non-invasive genetic test, which helps prevent hearing loss in newborns treated with antibiotics in NICUs, is gaining traction following a conditional recommendation from NICE. The company’s CEO expressed optimism for further NHS adoption and growing international opportunities.
For further insights into GB:GDR stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “…Lack of Confidence in the Israeli Management”: Microsoft Stock (NASDAQ:MSFT) Slips as Israeli Connections Examined
- “We Think Investors Can Buy Optimus For Free”: Piper Sandler Assessment Sends Tesla Stock (NASDAQ:TSLA) Blasting Up
- Hitting the $4 Wall: Starbucks Stock (NASDAQ:SBUX) Notches Up Despite New Value Competitor